CureVac - Ingmar Hoerr, CEO
Added on 29 Mar 2017
Watched
3,315
times
CureVac, a clinical stage biopharmaceutical company from Tübingen, Germany, is pioneering the field of mRNA-based technology platforms for medical purposes with which mRNA is specifically optimised and formulated. Since 2000 the company develops novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases – both under the brand RNActive®. CureVac has successfully established the first GMP (good manufacturing practice) facility worldwide for the manufacture of RNA and mRNA and has pioneered mRNA-based drugs in clinical studies.
REACTIES
Je account heeft geen avatar
Selecteer een tijdelijke avatar om verder te gaan met het plaatsen van reacties
Confirm
Er ging iets fout, probeer opnieuw a.u.b.
Or
Uploaden op Y8 Account
Annuleren